Category Archives: OTC

The Movie Studio, Inc. (MVES: OTC Pink Current) | The Movie Studio Inc. Announces Digital Distribution Content and Marketing Strategy for 2018

HALLANDALE BEACH, Fla., Dec. 14, 2017 (GLOBE NEWSWIRE) — The Movie Studio, Inc. (OTC:MVES) (the “Company”) proudly announces the introduction to Network Affiliates, Vendors and Content Providers The Movie Studio, Inc. acquisition of Emerging Pictures and new content and marketing initiative prior to re-integration of the proprietary asset movie theater commercial Video on Demand Network. Upon our new marketing initiative being embraced by the participants, the Company intends to accelerate on leveraging our content and marketing solution(s) via our direct access theatrical distribution network of over One Hundred and Fifty (150) theaters venues currently with digital servers targeted for 2018.

About The Movie Studio acquisition of Emerging Pictures

Emerging Pictures Commercial VOD (Video on Demand) platform is a B2B Netflix, Hulu or Amazon Prime for movie theaters. The platform provides seamless point to point distribution while lowering cost for theaters, film makers and distributors. The technology also totals consumer demand for motion pictures providing advanced analytics while utilizing the data to match and deliver content in order to capitalize on profits. This enables providers and exhibitors to be more effective and advanced in their distribution tactics and user interface design decisions.

Historically, the technology at hand has forced filmmakers and studios to provide physical copies of their films, DVDs or digital copies on hard drives to distributors and theaters across the globe. All too often the films are ultimately copied and pirated, resulting in a loss of revenues. Emerging Pictures Commercial VOD (Video on Demand) platform helps to prevent piracy with the goal of increasing overall revenues for film-makers, studios, distributors and theaters. The proprietary platform differentiates from the traditional process abolishing piracy of motion pictures. 

“By initiating vendor and theatrical application of the acquired proprietary commercial VOD platform developed by Emerging Pictures, The Movie Studio could maximize, utilize, enhance and expand its footprint to theatrical distribution and gain market share of our independent films and other films companies with possible revenue shares,” announced Lorne A. Wray, the Executive Vice President.

“The acquisition of the Emerging Pictures Platform in theater venues is positioned in the sector with a disruptive technology and combined with a disruptive marketing strategy could not only deliver movies to the theaters but also combine a digital out of home (DOOH), mobile and various print initiatives as ‘Traffic Drivers’ that could provide a unique model for large scale integration of our content,” Gordon Scott Venters, President and CEO stated today.

About The Movie Studio Inc.
The Movie Studio, Inc. is a vertically integrated motion picture production and distribution Company with completed motion picture and production assets. The Company acquires, develops, manufactures, and distributes independent motion picture content for worldwide consumption in Theatrical, Video on Demand (VOD), Foreign Sales and on various media devices. For more information, please go visit

Forward Looking Statements and Disclaimer
Statements made in this press release that express the Company or management’s intentions, plans, beliefs, expectations or predictions of future events, are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will” and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company’s actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results; levels of activity, performance or achievements and investors should not place undue reliance on the Company’s forward-looking statements. No information contained in this press release should be construed as any indication whatsoever of the Company’s future financial performance, future revenues or its future stock price. The forward-looking statements contained herein represent the judgment of the Company as of the date of this press release, and the Company expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues or results of operations.

The Movie Studio, Inc.
Gordon Scott Venters
President and CEO
Gulfstream Park 
800 Silks Run Suite 1330
Hallandale Beach, FL 33009

Article source:

Siyata Mobile, Inc. (SYATF: OTCQX International) | Siyata Mobile Announces Increase of CDN$1 Million to Brokered Private Placement resulting in up to CDN$4 Million in Unsecured Convertible Debentures

MONTRÉAL, Dec. 13, 2017 (GLOBE NEWSWIRE) — Further to its news release dated December 13, 2017, Siyata Mobile Inc. (the “Company” or “Siyata“) (TSX-V:SIM) (OTCQX:SYATF) is pleased to announce that it has increased the size of its previously announced brokered private placement financing from CDN$3,000,000.00 to CDN$4,000,000.00 (and, if exercised, up to an additional CDN$600,000.00 (up from the CDN$450,000.00 as previously announced on December 13, 2017) pursuant to the Agent’s Option (as defined below) through the issuance of unsecured convertible debentures (the “Convertible Debentures”) at a price of CDN$1,000.00 (the “Issue Price”) per Convertible Debenture (the “Offering”).

The Company will grant an option to require the Company to sell, at the sole discretion of the Lead Agent, up to an additional 600 Convertible Debentures at the Issue Price (the “Agent’s Option”) (up from the 450 Convertible Debentures previously announced on December 13, 2017) and otherwise on the same terms and conditions, exercisable in whole or in part upon providing written notice to the Company not less than forty-eight (48) hours prior to the closing date for the Offering (the “Closing Date”).

Each Convertible Debenture will be convertible into 1,667 common shares in the capital of the Company (“Common Shares”, and each a “Common Share”) representing approximately CDN$0.60 (the “Conversion Price”) per Common Share, subject to adjustment in certain events.

Each Convertible Debenture will bear interest at a rate of 10.5% per annum from the date of issue, payable in cash quarterly in arrears. Any unpaid interest payments will accrue and be added to the principal amount of the Convertible Debenture.

The Convertible Debentures will mature thirty (30) months (the “Maturity Date”) after the date of issuance and are convertible into Common Shares at the Conversion Price at the option of the holder at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the Maturity Date, and (ii) the date fixed for redemption in the event of a change of control.

On the Closing Date, each purchaser will receive one (1) non-transferrable share purchase warrant (each, a “Warrant”) for each CDN$1.00 principal amount of Convertible Debentures purchased by such purchaser. Each Warrant will entitle the holder to acquire one further Common Share (each, a “Warrant Share”) at an exercise price of CDN$0.70 per Warrant Share.  The Warrants will expire on the two year anniversary of the Closing Date.

The Lead Agent has the right to assemble a syndicate in accordance with standard industry practice (including the Lead Agent, the “Syndicate”) and in consideration of the services to be provided by the Syndicate, the Company shall pay a commission of 7% of the gross proceeds of the Offering, payable in Common Shares.

The Offering remains subject to the approval of the TSX Venture Exchange, as well as customary legal and business due diligence by the Syndicate. The securities issued pursuant to the Offering will be subject to a statutory hold period of four (4) months and one (1) day and the net proceeds from the Offering will be used for general working capital.   Net proceeds of the Offering will be used to fund general working capital and repay and close the operating credit margin facility of Signifi Mobile Inc. (a wholly owned subsidiary of the Company) with the National Bank of Canada and discharge the security associated therewith.

About Siyata

Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.

Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.

Visit and to learn more.

On Behalf of the Board of Directors of:


Marc Seelenfreund
CEO and Chairman

Investor Relations:
Arlen Hansen
Kin Communications

PCG Advisory Group:
Kirin Smith, Chief Operating Officer

Sales Department:
Glenn Kennedy, VP Sales
Siyata Mobile Inc.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Primary Logo

Article source:

CohBar Inc. (CWBR: OTCQX U.S.) | CohBar Announces Approval for Listing on the NASDAQ Capital Market

NASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR

MENLO PARK, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) — CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that The NASDAQ Stock Market LLC has approved the Company’s application to list its common stock on the NASDAQ Capital Market (NASDAQ).

CohBar’s common stock is expected to commence trading on the NASDAQ Capital Market at the opening of trading on December 15, 2017 under the ticker symbol CWBR. The Company’s common stock will continue to trade on the OTCQX until market close on December 14, 2017 under the ticker symbol CWBR. In addition to trading on the NASDAQ Capital Market, the Company’s common stock will also continue to trade on the TSX Venture Exchange under the ticker symbol COB.U.

“Listing on NASDAQ represents a major milestone for our Company and its shareholders, reflecting the significant progress our team has made in preparing CB4211 for clinical trials, and in securing our leadership position in the development of MBTs, a new class of therapeutics with the potential to treat a wide range of age-related diseases,” said Simon Allen, CohBar CEO. “We believe that our NASDAQ listing will significantly enhance our visibility in the marketplace, attract institutional investors, and ultimately help us to realize greater value for our shareholders as we expand our pipeline of novel therapeutics that harness the power of the mitochondria and its encoded peptides.”

About CohBar’s Lead Program 

CohBar’s lead preclinical development program is based on MOTS-c, a mitochondrial-derived peptide (MDP) that was discovered in 2012 by CohBar founder Professor Pinchas Cohen and his academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company is developing CB4211, a novel and improved analog of MOTS-c, for the treatment of nonalcoholic steatohepatitis (NASH) and obesity.

About CohBar

CohBar (OTCQX:CWBR) (TSXV:COB.U) is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

For additional company information, please visit

Forward-Looking Statements

This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations related to commencement of trading on the NASDAQ Capital Market, including the timing and anticipated benefits of such listing; statements regarding the therapeutic potential of its lead MBT candidate and other mitochondria based therapeutics, as well as the potential for additional discoveries. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the possibility of unfavorable study results or of delays or difficulties in commencing and completing clinical trials for its lead MBT candidate. Additional risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and obtain financing necessary to continue its operations and fund its candidate programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at or

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Investor and Media Contact:
Jeff Biunno, CFO
CohBar, Inc.
(650) 446-7888 ext. 109

Primary Logo

Article source:

Bunk Beds